MedTrace Logo

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

NCT05493995 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-05-09

No results posted yet for this study

Summary

It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer.

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

Penpulimab

Penpulimab 200 mg administered intravenously every 3 weeks.

DRUG

Anlotinib

12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

DRUG

Nab paclitaxel

125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.

DRUG

Gemcitabine

1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    collaborator INDUSTRY

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493995 on ClinicalTrials.gov